文献速递乳腺癌

三阴性乳腺癌中结构染色体不稳定性表型作为卡铂疗效生物标志物的评估:TNT试验

Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial.
PubMed 文献 · Ann Oncol · 2020-10-21

TNT试验中,研究者利用135例三阴性乳腺癌原发癌组织的SNP阵列数据,衍生7种已发表和2种新型的结构染色体不稳定性(CIN)定量指标,分析其与卡铂或多西他赛疗效的关系。结果显示,无HLAMP且CIN指标居中的肿瘤患者从卡铂治疗中获益更明显,提示原发肿瘤基因组不稳定程度与转移阶段治疗反应存在复杂悖论关系。

要点

  • 无HLAMP患者卡铂组ORR 56% vs 多西他赛组29%,PFS 6.1 vs 4.1个月,交互P=0.047。
  • 卡铂组中NtAI居中者ORR 54% vs 20%(P=0.03),AiCNA居中者ORR 62% vs 33%(P=0.076)。
  • 高AiCNA和高PGA患者卡铂组PFS较短,交互P分别为0.027和0.053。

核心结论

  • 无HLAMP且CIN指标居中的三阴性乳腺癌患者从卡铂治疗中获益优于多西他赛。
  • 原发肿瘤基因组不稳定程度与转移阶段治疗反应之间存在复杂且悖论性的关系。

研究设计与样本

  • TNT试验(NCT00532727)中,对135例三阴性乳腺癌原发癌FFPE组织行Illumina OmniExpress SNP阵列检测拷贝数畸变。
  • 衍生7种已发表CIN指标(AiCNA、AbCNA、CnLOH、NtAI、BRCA1-like、PGA、HRD评分)和2种新型指标(Shannon多样性指数SI、高水平扩增HLAMP)。
  • 连续CIN指标按三分位分组,分析客观缓解率(ORR)和无进展生存期(PFS)。

主要发现

  • 无HLAMP患者卡铂组ORR 56% vs 多西他赛组29%(P_HLAMP,quiet=0.085),PFS 6.1个月 vs 4.1个月(P_interaction/HLAMP=0.047)。
  • 卡铂组中NtAI居中者ORR 54% vs 多西他赛组20%(P_NtAI,intermediate=0.03)。
  • 卡铂组中AiCNA居中者ORR 62% vs 多西他赛组33%(P_AiCNA,intermediate=0.076)。
  • 高AiCNA患者卡铂组PFS 3.4个月 vs 低/中组5.7个月(P_interaction/AiCNA=0.027,P_adj.interaction/AiCNA=0.125)。
  • 高PGA患者卡铂组PFS 3.8个月 vs 低/中组5.6个月(P_interaction/PGA=0.053,P_adj.interaction/PGA=0.176),多西他赛组无差异。

关键数值与推荐

  • HLAMP定义为1q、8q和10p上至少存在一个前5%扩增的细胞遗传带。
  • 连续CIN指标按三分位分为低、中、高三组。

临床怎么用

  • 无HLAMP且CIN指标居中的三阴性乳腺癌患者可能优先考虑卡铂而非多西他赛。
  • 高AiCNA或高PGA患者卡铂组PFS较短,选择卡铂需谨慎。

局限性

  • 部分交互作用P值经校正后未达显著性(如AiCNA校正后P=0.125)。
  • 样本量有限(135例),结果为探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the TNT trial of triple negative breast cancer (NCT00532727), germline BRCA1/2 mutations were present in 28% of carboplatin responders. We assessed quantitative measures of structural chromosomal instability (CIN) to identify a wider patient subgroup within TNT with preferential benefit from carboplatin over docetaxel. PATIENTS AND METHODS: Copy number aberrations (CNAs) were established from 135 formalin-fixed paraffin-embedded primary carcinomas using Illumina OmniExpress SNP-arrays. Seven published [allelic imbalanced CNA (AiCNA); allelic balanced CNA (AbCNA); copy number neutral loss of heterozygosity (CnLOH); number of telomeric allelic imbalances (NtAI); BRCA1-like status; percentage of genome altered (PGA); homologous recombination deficiency (HRD) scores] and two novel [Shannon diversity index (SI); high-level amplifications (HLAMP)] CIN-measurements were derived. HLAMP was defined based on the presence of at least one of the top 5% amplified cytobands located on 1q, 8q and 10p. Continuous CIN-measurements were divided into tertiles. All nine CIN-measurements were used to analyse objective response rate (ORR) and progression-free survival (PFS). RESULTS: Patients with tumours without HLAMP had a numerically higher ORR and significantly longer PFS in the carboplatin (C) than in the docetaxel (D) arm [56% (C) versus 29% (D), PHLAMP,quiet = 0.085; PFS 6.1 months (C) versus 4.1 months (D), Pinteraction/HLAMP = 0.047]. In the carboplatin arm, patients with tumours showing intermediate telomeric NtAI and AiCNA had higher ORR [54% (C) versus 20% (D), PNtAI,intermediate = 0.03; 62% (C) versus 33% (D), PAiCNA,intermediate = 0.076]. Patients with high AiCNA and PGA had shorter PFS in the carboplatin arm [3.4 months (high) versus 5.7 months (low/intermediate); and 3.8 months (high) versus 5.6 months (low/intermediate), respectively; Pinteraction/AiCNA = 0.027, Padj.interaction/AiCNA = 0.125 and Pinteraction/PGA = 0.053, Padj.interaction/PGA = 0.176], whilst no difference was observed in the docetaxel arm. CONCLUSIONS: Patients with tumours lacking HLAMP and demonstrating intermediate CIN-measurements formed a subgroup benefitting from carboplatin relative to docetaxel treatment within the TNT trial. This suggests a complex and paradoxical relationship between the extent of genomic instability in primary tumours and treatment response in the metastatic setting.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Sipos O, Tovey H, Quist J, et al. Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. Ann Oncol. 2020. PMID: 33098992. doi:10.1016/j.annonc.2020.10.475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。